MedPath

A prospective study on prediction of sensitivity to trastuzumab using gene expression of peripheral blood mononuclear cells

Not Applicable
Conditions
bresat cancer
Registration Number
JPRN-UMIN000002660
Lead Sponsor
Chikako Shimizu, Kenji Tamura
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1. uncontrolled CNS metastasis 2. co-existence of heart failure or past history of decline in cardiac function during trastuzumab treatment 3. pregnant women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
response rate after enrichment by gene signature
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath